Disorder of Consciousness
Conditions
Keywords
Psychedelics, Complexity, Ketamine, Clinical Diagnosis, Consciousness level
Brief summary
The investigators will run a Randomized Clinical Trial with 30 patients with disorders of consciousness (DoC), with intravenous subanesthetic doses of ketamine. Patients will simultaneously undergo TMS-EEG. The piloting will be done on 3 patients, with EEG only.
Detailed description
The protocol will be organized in three phases: baseline, experimental, and follow-up. In the baseline, patients will receive a multimodal assessment \[functional magnetic resonance imaging (fMRI), positron emission tomography (PET), electroencephalogram (EEG)\]. The experimental phase is made of 2 sessions spaced 5 days apart: on day 1, patients will receive placebo (or ketamine), on day 5 patients will receive ketamine (or placebo). The order will be randomized and balanced. The investigators will use a targeted-controlled infusion (TCI) system to infuse a continuous subanesthetic dose of ketamine, which is known to have psychedelics effects, or a saline solution. The investigators will periodically assess for new signs of consciousness with the simplified evaluation of consciousness disorders (SECONDs) scale. The investigators will use transcranial magnetic stimulation coupled to EEG (TMS-EEG) to measure brain activity and calculate brain complexity. TMS-EEG will be performed from 20 minutes before the beginning of the infusion up to the max duration of the experiment (90 minutes). Another SECONDs will be performed on the following day of each session to control for carry-over effects. The primary outcomes are the emergence of new conscious behaviours and higher brain complexity following ketamine infusion. The secondary outcomes are baseline brain differences in neurophysiological and brain imaging measures between responders (new conscious behaviors or higher brain complexity) and non-responders (no new conscious behaviors or higher brain complexity). In the follow-up phase, patients' health will be evaluated at 1, 6, and 12 months.
Interventions
Intravenous solution (other info already provided)
DRUGPlacebo
Saline Solution
Sponsors
Centre Hospitalier Universitaire de Liege
William Lennox Neurological Center UCLouvain
University of Liege
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Masking description
One investigator not involved in the data acquisition and analysis, and the pharmacist who will prepare the syringe for the TCI will not be blind.
Intervention model description
Double-blind, placebo-controlled, cross-over RCT
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Clinically stable * Diagnosis of UWS or MCS based on repeated coma recovery scale-revised) (CRS-R) or SECONDs * More than 28 days post-insult * Informed consent from the legal representative of the patient
Exclusion criteria
* Neurological medications other than anti-spasticity drugs in the last 2 weeks or 4 half-lives * Previous neurological functional impairment other than related to their DoC * A history of psychotic disorders * Contraindication to MRI, EEG, PET or TMS * Use of nitrates or other vasodilators, central nervous system acting agents such as barbiturates, morphine and related drugs. * Use of drugs known to interact with ketamine (i.e., CYP3A4, diazepam, ...) * Coronary insufficiency * Other sympathomimetic drugs
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| New conscious behaviours | Max 90 minutes from Ketamine Infusion | New conscious behaviours (i.e., command following, visual pursuit) after the infusion of the ketamine as recorded via the simplified evaluation of consciousness disorders (SECONDs) behavioural scale, that are not seen before ketamine, during placebo infusion, or in baseline. The SECONDs has 8 items, with the most complex item linked to a higher conscious state. The score goes from 0 (coma) to 8 (emergent from the minimally conscious state). |
| Higher brain complexity | Max 90 minutes from Ketamine Infusion | Higher brain complexity \[perturbational complexity index (PCI) or Lempel-Ziv complexity (LZC)\] during the infusion of ketamine. The investigators expect complexity to increase when new conscious behaviors are observed. If the patient does not show new signs of consciousness but has high complexity, the investigators expect to record memories of the experience in the follow-up phase. PCI and LZC values range from 0 (no complexity) to 1 (high complexity). The investigators expect complexity values to be proportional to the concentration of the drug. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| PET biomarker | From baseline | Different baseline PET signal between responders (patients who show new signs of consciousness or higher brain complexity after the drug), and non-responders (who do not show new signs of consciousness or higher brain complexity). In particular, higher metabolism \[measured by standardized uptake value (SUV)\] in responders compared to non-responders. |
| MRI biomarker | From baseline | Different baseline MRI between responders (patients who show new signs of consciousness or higher brain complexity after the drug), and non-responders (who do not show new signs of consciousness or higher brain complexity). In particular, higher resting-state BOLD activity in responders compared to non-responders and more preserved brain structures. |
| EEG power | From baseline | Different baseline EEG signal between responders (patients who show new signs of consciousness or higher brain complexity after the drug), and non-responders (who do not show new signs of consciousness or higher brain complexity). In particular, higher alpha-band activity in responders compared to non-responders. |
Countries
Belgium
Contacts
Primary ContactPaolo Cardone, MSc
Backup ContactCharlotte Martial, PhD
Outcome results
None listed